Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application.

1. Cancelled
2. Cancelled
3. Cancelled
4. Cancelled
5. Cancelled
6. Cancelled
7. Cancelled
8. Cancelled
9. Cancelled
10. Cancelled
11. Cancelled
12. Cancelled
13. Cancelled
14. Cancelled
15. Cancelled
16. Cancelled
17. Cancelled
18. Cancelled
19. Cancelled
20. Cancelled
21. Cancelled
22. Cancelled
23. Cancelled
24. Cancelled

25. Cancelled

26. Cancelled

27. Cancelled

28. Cancelled

29. Cancelled

30. Cancelled

31. Cancelled

32. Cancelled

33. Cancelled

34. Cancelled

35. Cancelled

36. Cancelled

37. Cancelled

38. Cancelled

39. Cancelled

40. Cancelled

41. Cancelled

42. Cancelled

43. Cancelled

44. Cancelled

45. Cancelled

46. (New) A composition comprising glucosamine and an active egg fraction, wherein the active egg fraction is purified from an egg obtained from an egg-producing animal that has been hyperimmunized with an immunogenic vaccine, said immunogenic vaccine comprising antigens selected from the group consisting of bacterial, viral, protozoan, fungal and cellular immunogens and mixtures thereof.

47. (New) The composition of claim 46 wherein the active egg fraction comprises egg yolk.

48. (New) The composition of claim 47 wherein the active egg fraction comprises a partially purified anti-inflammatory fraction of the egg, wherein said fraction is purified from the egg yolk.

49. (New) The composition of claim 46 wherein the glucosamine is selected from the group comprising glucosamine HCI and glucosamine sulfate.

50. (New) The composition of claim 46 wherein the amount of glucosamine comprises between approximately 10 milligrams and 5 grams.

51. (New) The composition of claim 46 wherein the immunogenic vaccine comprises immunogens selected from the group consisting of: *Escherichia coli, Escherichia coli* (Aerobacter), *Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, Shigella dysenteriae, Salmonella enteriditis, Staphlococcus epidermidis, Staphylococcus simulans, Streptococcus pyogenes,* type 1, *Streptococcus pyogenes,* type 3, *Streptococcus pyogenes,* type 5, *Streptococcus pyogenes,* type 8, *Streptococcus pyogenes,* type 12,*Streptococcus pyogenes,* type 14, *Streptococcus pyogenes,* type 18, *Streptococcus pyogenes,* type 22, *Proteus vulgaris, Streptococcus agalactiae, Streptococcus mitis, Streptococcus mutans, Streptococcus salavarius, Streptococcus sanguis, Streptococcus pneumoniae, Propionibacterium acnes* and *Haemophilis influenzae*.

52. (New) A method for reducing serum fibrinogen levels in a subject, the method comprising administering to the subject an effective amount of a composition comprising glucosamine and an active egg fraction wherein the active egg fraction is purified from an egg obtained from an egg-producing animal which has been hyperimmunized with an immunogenic vaccine, said immunogenic vaccine comprising antigens selected from the group consisting of bacterial, viral, protozoan, fungal and cellular immunogens and mixtures thereof.

53. (New) The method of claim 52 wherein the effective amount of glucosamine comprises between approximately 10 milligrams and 5 grams.

54. (New) The method of claim 52, wherein the composition is administered by a method selected from the group consisting of parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intranasally, orally and topically.

55. (New) The method of claim 52 wherein the active egg fraction is dried to form a dried powder.

56. (New) A method for reducing or preventing the onset of rheumatoid arthritis in a subject, the method comprising administering to the subject an effective amount of a composition comprising glucosamine and an active egg fraction wherein the active egg fraction is purified from an egg an egg-producing animal which has been hyperimmunized with an immunogenic vaccine, said immunogenic vaccine comprising antigens selected from the group consisting of bacterial, viral, protozoan, fungal and cellular immunogens and mixtures thereof.

57. (New) The method of claim 56 wherein the effective amount of glucosamine comprises between approximately 10 milligrams and 5 grams.

58. (New) The method of claim 56 wherein the composition is administered by a method selected from the group consisting of parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intranasally, orally and topically.

59. (New) The method of claim 56 wherein the active egg fraction is dried to form a dried powder.